DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03122431 (ClinicalTrials.gov)	June 5, 2017	17/4/2017	Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases	Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects	Systemic Lupus Erythematosus (SLE);Juvenile SLE;Cutaneous Lupus	Drug: Thalidomide;Drug: Hydroxychloroquine reduced;Drug: Hydroxychloroquine high	University of Sao Paulo General Hospital	Fundação de Amparo à Pesquisa do Estado de São Paulo	Recruiting	5 Years	64 Years	All	296	Phase 4	Brazil

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03122431
(ClinicalTrials.gov)

June 5, 2017

17/4/2017

Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases

Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects

Systemic Lupus Erythematosus (SLE);Juvenile SLE;Cutaneous Lupus

Drug: Thalidomide;Drug: Hydroxychloroquine reduced;Drug: Hydroxychloroquine high

University of Sao Paulo General Hospital

Fundação de Amparo à Pesquisa do Estado de São Paulo

Recruiting

5 Years

64 Years

All

296

Phase 4

Brazil